Yiteng Jiahe (06998): GB268 phase IB/II clinical trial completed first patient administration

Zhitongcaijing · 1d ago

Zhitong Finance App News, Yiteng Jiahe (06998) announced that the Phase IB/II clinical trial of the company's highly differentiated and innovative PD-1/CTLA-4/VEGF tri-specific antibody GB268 for the treatment of locally advanced unresectable or metastatic breast cancer (including triple-negative breast cancer TNBC and hormone receptor positive/HER2 negative HR+/ HER2- breast cancer) successfully completed the first patient administration on August 5, 2026.

The study included monotherapy, immuno-combination chemotherapy, and immune-combination antibody conjugate drug combinations. The main study endpoints were to evaluate the safety and tolerability of GB268 combined treatment, including dose-limiting toxicity (DLT), and to evaluate the initial antitumor activity of GB268 single drugs and combinations of different treatment regimens in corresponding breast cancer patients.

The clinical plan runs through the entire frontline and later-line treatment stages, taking the first step in expanding the scope of application of GB268 in all aspects. In the future, the company also plans to carry out multiple combined treatment clinical studies in more advanced solid tumors. GB268 single-agent phase I clinical data is scheduled to be announced in the European Society of Medical Oncology (ESMO) in the fourth quarter of 2026.